摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

cobalt(II) chloride hexahydrate

中文名称
——
中文别名
——
英文名称
cobalt(II) chloride hexahydrate
英文别名
cobalt chloride hexahydrate;[Co(H2O)6]Cl2;Cobalt(2+);chloride;hydrate
cobalt(II) chloride hexahydrate化学式
CAS
——
化学式
2Cl*Co*6H2O
mdl
——
分子量
237.991
InChiKey
PXKSCOOGDMNFFL-UHFFFAOYSA-M
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -3.82
  • 重原子数:
    3
  • 可旋转键数:
    0
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    1
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    cobalt(II) chloride hexahydrate尿素 作用下, 以 为溶剂, 反应 12.0h, 生成
    参考文献:
    名称:
    Ultrathin nanosheets constructed CoMoO4porous flowers with high activity for electrocatalytic oxygen evolution
    摘要:
    由超薄纳米片组装而成的分层 CoMoO4 微流体在氧气进化方面的电催化活性和稳定性大大高于 IrO2 基准。
    DOI:
    10.1039/c5cc05511c
  • 作为产物:
    参考文献:
    名称:
    Synthesis of cationic cobalt(II) complexes and their efficiency as catalysts for the polymerization of 1,3-butadiene
    摘要:
    A series of novel cationic cobalt( II) compounds accompanied by various counter ions ([ BF4], [ PF6] , [ SbF6]) and N- bearing ligands ( 1,10- phenanthroline, bipyridine, benzimidazole, and imidazole) were synthesized. Neutral compounds, CoCl2- nLigands, were prepared as reference compounds. All the compounds were characterized using IR spectral analysis and elemental analysis and some of the compounds were further characterized by single- crystal X- ray diffraction analysis. The synthesized compounds were evaluated as precursors for butadiene polymerization in conjunction with ethylaluminum sesquichloride as a cocatalyst, and the polymerization mechanism was proposed to involve anionic coordination polymerization. The active centers of the catalysts were cationic in nature, and the catalytic activities were affected by the electronegativity of the counter ion.
    DOI:
    10.1016/j.ica.2014.01.012
  • 作为试剂:
    描述:
    1,1,1-三(羟甲基)乙烷 在 sodium tetrahydroborate 、 cobalt(II) chloride hexahydrate 、 sodium hydroxide 作用下, 以 甲醇 为溶剂, 生成
    参考文献:
    名称:
    Biomimetic ferrichrome: structural motifs for switching between narrow- and broad-spectrum activities in P. putida and E. coli
    摘要:
    具有铁铬样活性的模拟物使得可以制定广谱活性化合物的指导方针。偏离这些指导方针会提供窄谱活性化合物。
    DOI:
    10.1039/c5dt02685g
点击查看最新优质反应信息

文献信息

  • (Arylsulfonamido- and pyridyl-)-substituted carboxylic acids and
    申请人:Ciba-Geigy Corporation
    公开号:US05025025A1
    公开(公告)日:1991-06-18
    Disclosed are the compounds of formula ##STR1## wherein A represents lower alkylene; B represents oxygen, sulfur, lower alkylene, lower alkylene interrupted by oxygen, sulfur, sulfinyl or sulfonyl, (oxy-, sulfinyl-, sulfonyl- or thio)-lower alkylene, lower alkenylene, phenylene or a direct bond; M represents lower alkylene, lower alkylene interrupted by oxygen, sulfur, sulfinyl or sulfonyl, (oxy-, sulfinyl, sulfonyl- or thio)-lower alkylene, lower alkenylene or a direct bond; or one of A, B and M represents lower alkylidenylene and the other two independently represent lower alkylene; R represents hydrogen unless A, B or M represents lower alkylidenylene in which case R represents the second bond to the adjacent aklylidenylene unsaturated carbon atom; Het represents 1-imidazolyl, 3-pyridyl, or 1-imidazolyl or 3-pyridyl substituted by lower alkyl; Ar represents carbocyclic or heterocyclic aryl; pharmaceutically acceptable ester and amide derivatives thereof; the N-oxides of said compounds wherein Het represents optionally substituted pyridyl; the said compounds of formula I wherein COOH is replaced by 5-tetrazolyl; and the pharmaceutically acceptable salts; which are useful as thromboxane synthetase inhibitors and thromboxane receptor antagonists.
    揭示了以下式的化合物##STR1##其中A代表较低的烷基; B代表氧、、较低的烷基、被氧、、亚砜或磺酰中断的较低的烷基、(氧基、亚砜基、磺酰基或基)-较低的烷基、较低的烯基、苯基或直接键; M代表较低的烷基、被氧、、亚砜或磺酰中断的较低的烷基、(氧基、亚砜基、磺酰基或基)-较低的烷基、较低的烯基或直接键; 或者A、B和M中的一个代表较低的烷基亚烯基,另外两个独立地代表较低的烷基; R代表氢,除非A、B或M代表较低的烷基亚烯基,在这种情况下R代表相邻烷基亚烯基不饱和碳原子的第二键; Het代表1-咪唑基、3-吡啶基,或者被较低烷基取代的1-咪唑基或3-吡啶基; Ar代表碳环或杂环芳基; 其药学上可接受的酯和酰胺衍生物; 其中Het代表可选择取代的吡啶基的N-氧化物; 公式I中COOH被5-四唑基取代的所述化合物; 和药学上可接受的盐; 这些化合物可用作血栓素合酶抑制剂和血栓素受体拮抗剂。
  • Substituted pyrrolidin-3-yl-alkyl-piperidines
    申请人:Merrell Pharmaceuticals Inc.
    公开号:US05635510A1
    公开(公告)日:1997-06-03
    The present invention relates to substituted pyrrolidinyl-3-yl-alkyl-piperidines, their stereoisomers, and pharmaceutically acceptable salts thereof and processes for preparation of the same. The compounds of the present invention are useful in their pharmacological activities such as tachykinin antagonism, especially substance P and neurokinin A antagonism, and the like. Compounds having the property of tachykinin antagonism are indicated for conditions associated with neurogenic inflammation and other diseases described herein.
    本发明涉及取代吡咯啉基-3-基-烷基-哌啶、其立体异构体和药学上可接受的盐以及其制备方法。本发明的化合物在药理活性方面具有用途,如快速激肽拮抗作用,特别是物质P和神经激肽A的拮抗作用等。具有快速激肽拮抗性质的化合物适用于与神经源性炎症和本文所述的其他疾病相关的情况。
  • Carboxysubstituted cyclic carboxamide derivatives
    申请人:Hoechst Marion Roussel, Inc.
    公开号:US05977139A1
    公开(公告)日:1999-11-02
    The present invention relates to novel carboxy substituted cyclic carboxamide derivatives of formula (1), ##STR1## and stereoisomers and pharmaceutically acceptable salts thereof and their use as tachykinin receptor antagonists. Such antagonists are useful in the treatment of tachykinin-mediated diseases and conditions disclosed herein including: asthma, coughs and bronchitis.
    本发明涉及新型的带有羧基取代的环戊酰胺衍生物化学式为(1),##STR1##及其立体异构体和药学上可接受的盐,以及它们作为速激肽受体拮抗剂的用途。这类拮抗剂在治疗包括哮喘、咳嗽和支气管炎在内的速激肽介导的疾病和症状中很有用。
  • Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl)
    申请人:Hoechst Marion Roussel, Inc.
    公开号:US05932571A1
    公开(公告)日:1999-08-03
    The present invention relates to novel N-methyl-N-(4-(4-(1H-benzimidazol-2-yl)\x9b1,4!diazepan-1-yl)-2-(aryl)butyl)b enzamide derivatives of the formula: ##STR1## stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonists. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.
    本发明涉及新型N-甲基-N-(4-(4-(1H-苯并咪唑-2-基)\x9b1,4!二氮杂环己烷-1-基)-2-(芳基)丁基)苯酰胺衍生物的公式:##STR1## 其立体异构体,以及其药学上可接受的盐,可用作组胺受体拮抗剂和速激肽受体拮抗剂。这类拮抗剂在过敏性鼻炎的治疗中很有用,包括季节性鼻炎和鼻窦炎;炎症性肠病,包括克罗恩病和溃疡性结肠炎;哮喘;支气管炎;以及呕吐。
  • Carboxy substituted acylic carboxamide derivatives
    申请人:Aventis Pharmaceuticals Inc.
    公开号:US06316445B1
    公开(公告)日:2001-11-13
    The present invention relates to novel carboxy substituted acyclic carboxamide derivatives of formula (1)): and stereoisomers and pharmaceutically acceptable salts thereof and their use as tachykinin receptor antagonists. Such antagonists are useful in the treatment of tachykinin-mediated diseases and conditions disclosed herein including: asthma, cough, and bronchitis.
    本发明涉及新型的带有羧基取代的无环羧酰胺衍生物化学式(1))及其立体异构体和药学上可接受的盐,以及它们作为速激肽受体拮抗剂的用途。这类拮抗剂在治疗包括哮喘、咳嗽和支气管炎在内的速激肽介导的疾病和症状中很有用。
查看更多